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Abstract
Background: Many studies have shown that colon cancer is an estrogen-dependent carcinoma.
This study explored the efficacy of endocrine therapy in colon cancer cells with high metastatic
potential (HT29). We investigated the proliferation of HT29 cells after exposure to endocrine
therapy (tamoxifen) and 5-FU.
Methods: Apoptosis was evaluated using flow cytometry. The expression of matrix
metalloproteinases 7 (MMP-7) and estrogen receptor beta (ERβ) was measured by reverse
transcription-polymerase chain reaction (RT-PCR) and western blot. The migration capability of
treated cells was determined with wound scratch assay.
Results: Tamoxifen alone, 5-FU alone, and the combination of the two drugs can significantly
inhibit HT29 cell proliferation and migration, block the cells in G2/M phase and induce cell
apoptosis. These drugs also can down-regulate MMP7 and ERβ expression.
Conclusion: Our findings suggest that endocrine therapy is an efficient therapy for inhibiting ERβ-
positive colon cancer cell proliferation and migration via down-regulation of MMP7.
Background
Colorectal cancer is a growing health problem. In 2002
over one million new cases of colorectal cancer were diag-
nosed, and 529,000 people died from the disease, with
the majority of deaths attributable to distant metastases
[1]. The liver is a frequent site of colorectal metastases,
and 15% to 25% of these patients have liver metastases at
diagnosis [2]. About 50% to 60% of colorectal cancer
patients will eventually develop advanced or metastatic
disease [3]. Despite advances in survival with chemother-
apy or surgical resection of hepatic metastases, the major-
ity of patients still experience disease recurrence [4].
Many studies observed that the estrogen receptor beta
(ERβ) is significantly related to cancer metastases [5-7].
Kuiper et al. first characterized ERβ in the rat prostate and
ovary [8]. ERβ is the dominant receptor in human colonic
mucosa, as many studies have shown that ERβ is more
highly expressed than ERα in colon tissue [9-12]. Animal
studies also revealed roles for ERβ in many tissues and
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tral prostate, salivary gland, immune system and central
nervous system [13-17]. Currently, ERβ is the only ER
identified in colon cell lines [10].
ERα and ERβ belong to a super-family of nuclear hor-
mone receptors that function as transcription factors
when they are bound to estrogens [18]. However, when
selected ER modulators (SERMs), such as tamoxifen
(TAM), bind to ERβ, they act as agonists rather than antag-
onists [19]. Additionally, Motylewska et al. showed that
TAM exerted a very early and potent inhibitory effect on
cancer cells, inducing total inhibition of cancer growth at
a concentration of 10-4 M [20].
Multiple factors, such as alterations in matrix metallopro-
teinases (MMPs), seem to be associated with polyp devel-
opment. MMPs are a family of zinc-dependent [21,22]
and calcium-dependent [22] endopeptidases that degrade
matrix glycoproteins [21,23]. Eighteen types of MMPs,
which play an important role in tumor invasion and
metastases, have already been identified [24,25]. MMP7
(matrilysin) was first detected from the conditioned
medium of a human rectal carcinoma cell line CaR-1 by
Miyazaki et al. [26]. MMP7 is a target gene of the Wnt
pathway, is an important biomarker of colorectal cancer
ecurrence and metastases, and is overexpressed in malig-
nant tumor and CRC liver metastases [27-29]. Gorodeski
reported that estrogen may decrease the activation of
MMP7 in vivo [30]. Thus, endocrine therapy may play a
role in treating hormone-dependent cancers by decreasing
the metastases that are caused by MMP7 activation. To test
this hypothesis, we examined the ability of TAM to
decrease MMP7 activation in the ERβ-positive colon can-
cer cell line HT29.
Methods
Cell culture and treatment
HT-29 cells are highly metastatic colon carcinoma cells
that were obtained from the American Type Culture Col-
lection, Rockville, MD, USA. Cells were maintained in
Dulbecco's modified Eagle medium supplemented with
10% fetal calf serum at 37°C in a humidified atmosphere
of 5% CO2.
Drug administration schedules
TAM and fluorouracil (5-FU) were purchased from Sigma
(St Louis, MO). The drug-exposure schedules, which are
summarized in Table 1, were as follows: (a) no treatment;
(b) TAM alone (1 × 10-7, 1 × 10-6, 1 × 10-5, or 1 × 10-4 M)
for 48 h; (c) 5-FU alone (6.25, 12.5, 25, or 50 μM) for 72
h; (d) 12.5 μM 5-FU for 24 h followed by 12.5 μM 5-FU
plus indicated TAM for 48 h. The experiments were per-
formed in triplicate for each time point, and the means ±
SD were calculated. Appropriate amounts of drug solution
were added directly to the growth medium the day after
plating. Control cells were plated in growth medium sup-
plemented with 0.1% DMSO.
Drug sensitivity, as indicated by the MTT assay
To induce cell death, cells were treated with either TAM
(Sigma, Cat. No. T-9262) dissolved in DMSO or 5-FU. The
final concentrations ranged from 1 × 10-7 to 1 × 10-4 M for
TAM and from 6.25 to 50 μM for 5-FU. To test the cytotox-
icity of each drug, HT-29 cells in the exponential growth
phase were seeded into 96-well cell plates in 100 μl of cul-
ture medium for 24 h prior to drug exposure and then
treated with various concentrations of TAM, 5-FU, or a
combination of these drugs. Cytotoxicity was evaluated
using a tetrazolium-based semi-automated colorimetric
(MTT) assay, with an ELISA reader at OD490.
Flow cytometry analysis
HT-29 cells were seeded in 6-well plates at a density of 4 ×
106 cell/well. Cells were treated with various concentra-
tions of each drug for the appropriate times, incubated at
37°C, fixed in 70% ethanol, and labeled with propidium
iodide solution (50 μg/ml; Sigma-Aldrich). The DNA con-
tent and cell cycle distribution of approximately 1 × 106
stained cells were analyzed using a FACScan flow cytome-
ter (Becton Dickinson).
Reverse transcriptase-polymerase chain reaction (RT-
PCR)
Total RNA was isolated from 4 × 106 cells by TRIzol (Inv-
itrogen, Carlsbad, CA, USA) according to the manufac-
turer's instructions. RNA was reverse transcribed in a total
volume of 20 μl containing 2 μg RNA, 0.5 μg olig (dT)15,
and 15 μl DEPC-treated water. Reverse transcription reac-
tion was incubated at 30°C for 10 min, 48°C for 30 min,
and 99°C for 5 min. After RT, the product was used to
amplify MMP7, ERβ and normalized based on β-actin
cDNA. PCR was performed using cDNA PCR kits (Takara,
Cat. DRR019A, Japan) in a final volume of 50 μl accord-
ing to the manufacturer's instructions. Amplification con-
ditions were performed for 30 cycles (denaturation at
94°C for 1 min, annealing at 54°C for 1 min, and exten-
sion at 72°C for 1 min). The MMP7 primers were 5'-AGA
TGT GGA GTG CCA GAT GT-3' (forward) and 5'-TAG ACT
GCT ACC ATC CGT CC-3' (reverse). The ERβ primers were
Table 1: Schedule of each group of treatment for three different 
times
Group 24 h 48 h 72 h
(a) no treatment
(b) TAM TAM
(c) 5-FU 5-FU 5-FU
(d) 5-FU 5-FU+TAM 5-FU+TAMPage 2 of 8
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2009, 28:132 http://www.jeccr.com/content/28/1/1325'-TGC TTT GGT TTG GGT GAT TGC-3' (forward) and 5'-
TTT GCT TTT ACT GTC CTC TGC-3' (reverse). The β-actin
primers were 5'-CGG GAC CTG ACT GAC TAC CTC A-3'
(forward) and 5'-TCA AGA AAG GGT GTA ACG CAA CTA-
3' (reverse). The PCR products were separated by electro-
phoresis on a 2% agarose gel and visualized by ethidium
bromide staining and UV illumination. The expected sizes
of the amplification products were 365 base pairs (bp) for
MMP7, 259 bp for ERβ, and 656 bp for β-actin.
Western blotting
HT-29 cells were exposed to TAM, 5-FU, or their combina-
tions for various time points in various administration
sequences. After treatment, 5 × 106 cells were collected for
protein extraction. Cell pellets were washed in PBS twice
and then lysed in 80 μl lysis buffer (0.1% SDS, 50 mmol/
L Tris·HCl pH 8.0, 150 mmol/L NaCl, 1 mmol/L EDTA,
100 μg/ml PMSF, 1 μg/ml Aprotinin, 1% NP-40) for 30
min on ice. After centrifugation at 12,000 rpm for 5 min
at 4°C, the supernatants were collected and frozen at -
80°C until analysis. Forty micrograms of total protein
were loaded in each well of a 10% SDS-PAGE gel. Proteins
were transferred to Hybond P polyvinylidene fluoride
membranes (Amersham Pharmacia Biotech, Amersham,
UK), which were then blocked in 5% dried skimmed milk
powder in TBST (Tween 20/TBS) for 3 h at room temper-
ature. Membranes were probed with primary antibodies
(mouse monoclonal MMP7 and ERβ antibody, 1/1000)
and then horseradish peroxidase-conjungated second
antibody. After washing, the immunoreactive protein was
detected using chemiluminescence (Cell Signaling).
Wound scratch assay
HT29 cells (2 × 105) were cultured to confluent cell mon-
olayers in medium containing 10% FBS on 6-well tissue
culture dishes. Cells were carefully wounded using sterile
20-μl pipette tips. The wounded monolayers were washed
twice with PBS to remove nonadherent cells and incu-
bated at 37°C in complete media. The cells were then
incubated in TAM (according to the drug administration
schedule) for 24 h, 48 h, or 72 h. The wound edges were
imaged by phase-contrast microscopy, and the extent of
migration was analyzed using the NIH image software
http://rsb.info.nih.gov/nih-image/Default.html.
Statistical analysis
The results are presented as the mean ± SD. P values less
than 0.05 were considered statistically significant.
Results and Discussions
Effects of each treatment on proliferation and apoptosis 
of HT29 cells
Proliferation of HT29 cells was not inhibited by the lower
doses (10-7 and 10-6 M) of TAM at 24 and 48 h but was sig-
nificantly inhibited in a dose- and time-dependent man-
ner by the higher doses (10-5 and 10-4 M) (Figure 1). On
the contrary, HT29 cells were significantly affected by 5-
FU in the range of concentrations between 6.25 and 50
Cytotoxic effect of TAM, 5-FU or a combination of these two drugs on HT29 cellsFigure 1
Cytotoxic effect of TAM, 5-FU or a combination of these two drugs on HT29 cells. Each point is the mean ± SD of 
three separate experiments. *P < 0.05, TAM vs. 12.5 μM 5-FU; ‡ P < 0.05, 12.5 μM 5-FU vs. 12.5 μM 5-FU+TAM.Page 3 of 8
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the lower dose of 5-FU (12.5 μM) combined with the var-
ious doses of TAM (10-7, 10-6, 10-5 and 10-4 M) to treat the
cells. Using 12.5 μM 5-FU in combination with TAM
showed significant inhibition of the rate of HT29 cell pro-
liferation compared to single treatments (Figure 1).
We analyzed the cell cycle distribution after drug treat-
ment and found evidence of a preferential block of colon
cancer cells in the G2/M phase. In cells treated with TAM,
when the drug concentration is increased from 10-7 to 10-
4 M, the percentage of cells in the G2/M phase decreased
from approximately 9.1 to 2.4% and the percentage of
cells in the G0/G1 phase decreased from 75.9 to 30%.
Increasing the dose of 5-FU, resulted in a growth arrest at
S phase, and the colon cancer cells were completely
blocked in G2/M phase. When 12.5 μM 5-FU was com-
bined with increasing doses of TAM, a decreased percent-
age of cells was detected in G0/G1 phase, and cells were
completely blocked in G2/M phase (Table 2).
Flow cytometry analysis confirmed the apoptosis rates of
HT29 cells under each treatment. Based on the DNA his-
tograms, 2.5, 2.9, 3.1 and 69.9% of the cells treated with
1 × 10-7, 1 × 10-6, 1 × 10-5 and 1 × 10-4 M TAM for 48 h
were in sub-G1 phase. Among cells treated with increasing
doses (6.25-50 μM) of 5-FU for 72 h, 9.3, 9.9, 12 and
20.2% of cells were in sub-G1 phase. When the two drugs
were combined (12.5 μM 5-FU with each dose of TAM)
for 72 h, 7.5, 12.5, and 17.8% of cells were in sub-G1
phase, These differences were significantly increased com-
pared to control HT29 colon cancer cells (1.9%) (Figure
2).
Migration capability of colon cancer cells treated TAM 
alone and in combination with 5-FU
The ability of tumor cells to migrate is closely associated
with their metastatic potential, and the wound scratch
assay was conducted to measure this potential. The per-
centage of migration area covered after 72 h was 71.6 ±
5.9% for control cells; 34.9 ± 1%, 11.1 ± 0.4% and 4.9 ±
0.4% for cells treated with TAM (10-7, 10-6 and 10-5 M,
respectively); and 55 ± 0.4%, 20.1 ± 0.2% and 18.8 ±
0.4% for cells treated with 5-FU (12.5, 25 and 50 μM,
respectively). The percentage of migration area of the drug
treatments was significantly lower than that of the control
cells (P < 0.0001). Based on the above results, the lower
dose of 5-FU (12.5 μM) was combined with each dose of
TAM (10-7, 10-6 and 10-5 M) for further assays. The per-
centage of migration area for the combined treatment was
65 ± 2%, 19.5 ± 1% and 1.4 ± 0.2% at 10-7, 10-6 and 10-5
M TAM, respectively (Figure 3). The anti-metastatic effect
of TAM on HT29 cells was confirmed to be dose-depend-
ent, and it was co-effect with 5-FU at higher dose as well.
As the wound gap is dismissed (because of cell death) in
the cells under the treatment of 10-4M TAM and the
almost same results of control group and 6.25 μM 5-FU,
so we discard the results of these two concentrations in
this part.
Effects of TAM and 5-FU on MMP7 and ERβ mRNA 
expression
We were interested in determining whether the MMP7
and ERβ genes could be inhibited by TAM and 5-FU. We
performed RT-PCR with MMP7 and ERβ primers on
cDNA that was reverse transcribed from RNA isolated
from HT29 cells. As expected, MMP7 mRNA was down-
regulated in a concentration-dependent manner after
incubation with different concentrations of TAM, 5-FU,
and the combination of these two drugs. However, the
ERβ mRNA was not significantly altered by the treatments
(Figure 4).
Table 2: Effects of each drug on cell cycle in HT29 cell
Group G1 (%) G2/M (%) S (%)
Control 82.2 ± 5.4 2.2 ± 0.5 15.5 ± 1.8
TAM (M) 10-7 75.9 ± 5.7 9.1 ± 2.1 15 ± 2.5
10-6 75.8 ± 4.5 9.2 ± 1.9 15 ± 2.1
10-5 63.2 ± 5.1 7.3 ± 1.4 29.5 ± 3.4
10-4 30 ± 5.6 2.4 ± 0.6 67.6 ± 4.5
5-FU (μM) 6.25 66.7 ± 5.4 0 33.3 ± 3.8
12.5 71.1 ± 6.2 0 28.9 ± 4.2
25 73.7 ± 7.4 0 26.3 ± 3.2
50 79.8 ± 7.7 0 20.2 ± 3.1
12.5 μM 5-FU +TAM (M) 10-7 75.0 ± 8.1 0 25.0 ± 4.2
10-6 67.8 ± 6.3 0 32.2 ± 3.1
10-5 51.8 ± 5.5 0 48.2 ± 4.7
Each value is the mean ± SD of three separate experiments.Page 4 of 8
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and ERβ protein expression in HT29 cells
We confirmed that HT29 cells express ERβ but do not
express ERα (data not shown). TAM (10-4 and 10-5 M)
down-regulated MMP7 and ERβ protein levels after 48 h.
Treatment of HT29 cells with 5-FU (0, 6.25, 12.5, 25, 50
μM) for 72 h showed a trend of diminished expression of
MMP7, but it significantly down-regulated ERβ protein
levels only when given at 50 μM. The combination treat-
ment of 12.5 μM 5-FU and each dose of TAM significantly
diminished expression of MMP7 and ERβ. Additionally
ERβ protein level was completely down-regulated in
response to 12.5 μM 5-FU plus 10-5 M TAM (Figure 4).
In this paper, we present two important findings. First,
SERMs such as TAM alone and in combination with 5-FU
can act as a chemo-endocrine therapy that efficiently
inhibits the proliferation and induces the apoptosis of
ERβ-positive colon cancer cells. Second, TAM alone and in
combination with 5-FU can effectively inhibit the migra-
tion of ERβ-positive colon cancer cells by down-regulating
MMP7 and ERβ expression. To determine whether TAM
Effect of each drug on apoptosis in HT29 colon cancer cellsFigure 2
Effect of each drug on apoptosis in HT29 colon cancer cells. The ratio of apoptotic cells increased in dose-dependent 
manner which were measured in HT29 cells treated with combined drugs (12.5 μM 5-FU with each dose of TAM), TAM and 5-
FU, respectively.Page 5 of 8
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cells, an ERβ-positive colon cancer cell line HT29 was
treated by TAM alone and in combination with 5-FU. As
shown in Figure 4, ERβ and MMP7 were present in HT29
cells and were inhibited following TAM and 5-FU treat-
ment. These genes were especially down-regulated by the
treatment of TAM and 5-FU together.
TAM is an antiestrogenic compound with a pure ERα
selective partial agonist/antagonist activity and a pure β
selective antagonist activity. These effects result in the
down-regulation of ERs. It is the first drug in the class of
SERMs [31-33]. Several SERMs are currently in various
stages of clinical testing. A recent study by Motylewska et
al[20] indicates that TAM and estradiol inhibit colon can-
cer growth and increase the cytotoxic effect of FU. This
study confirmed the importance of hormone steroids in
colon carcinogenesis and even suggested new therapeutic
schemes.
Endocrine therapy of colorectal carcinoma has been sug-
gested for decades, and there is some evidence to support
its use on colon cancer. Epidemiological data and gender
differences in the incidence of colon cancer suggest that
colon cancer is a hormone-dependent cancer. ERβ was
identified and is the predominant ER in colon tissue [12],
Cell migration of HT29 colon cancer cells over a 72-h period in response to different drugs after compared as determined with th  wound scratch assay (values are m an ± SD of t re  n ependent experim nts)Figure 3
Cell migration of HT29 colon cancer cells over a 72-h period in response to different drugs after compared as 
determined with the wound scratch assay (values are mean ± SD of three independent experiments).Page 6 of 8
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with negligible expression of ERα, suggests that ERβ is
involved in the protective effect of endocrine therapy on
colonic carcinogenesis. In addition, ERβ inhibits tumor
cell invasion and migration [6]. Based on the above evi-
dence, we tested cell migration in response to the different
drug treatments by cell scratching assay. Our results sup-
port the hypothesis that ERβ-positive cell migration can
be inhibited by endocrine therapy.
Our data clearly demonstrated that MMP7 was down-reg-
ulated by TAM, which induces apoptosis through ERβ.
Some researchers have reported that ERβ induces apopto-
sis in colon cancer Lovo cells due to increased p53 signal-
ing and have proposed that a reduction in β-catenin
protein is the cause of inhibition of cell proliferation [34].
MMP7 overexpression is an early event in the carcinoge-
netic cascade as normal colonic mucosa progresses to ade-
noma [35]. β-catenin, bound to T cell factor in the
cytoplasm, enters the nucleus and promotes the expres-
sion of target genes including cyclo-oxygenese, c-myc and
MMP7. These proteins are overexpressed in colorectal can-
cer, and a positive correlation has been demonstrated
between nuclear β-catenin protein levels and MMP7 tran-
scription in colorectal cancer [36]. Others have also dem-
onstrated that MMP7 protein and mRNA are consistently
expressed in liver metastases [29,37]. Thus, we suggest
MMP7 as a therapeutic target for endocrine therapy of
colorectal carcinoma.
Conclusion
The results support endocrine therapy as an efficient ther-
apy for colon cancer cells. Additionally, chemo-endocrine
therapy can also effectively down-regulate MMP7, which
in turn can influence tumor cell invasion and migration.
Further morphological studies in ER knockout models
should clarify the role of ERβ in colon tissue and confirm
the results from our cytology studies.
Abbreviations
ERβ: Estrogen Receptor Beta; 5-FU: Fluorouracil; MMPs:
Matrix Metalloproteinases; MMP-7: Matrix Metalloprotei-
nases 7; RT-PCR: Reverse Transcription Polymerase Chain
Reaction; SERMs: Selected ER Modulators; TAM:
Tamoxifen.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YJF participated in the study design, performed the data
analysis, draft the manuscript. PZZ, LLR and LZH partici-
pated in the study design and helped draft the manuscript.
ZLY performed the experiments. WDS was responsible for
the overall study design. All authors read and approved
the final manuscript.
Acknowledgements
This study has been supported by the Guangdong Foundation for Medical 
Scientific Research (A2009209) of China.
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics,
2002.  CA: a Cancer Journal for Clinicians 2005, 55:74-108.
2. Midgley R, Kerr D: Colorectal cancer.  Lancet 1999, 353:391-399.
3. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D: Ran-
domised comparison of combination chemotherapy plus
supportive care with supportive care alone in patients with
metastatic colorectal cancer.  BMJ 1993, 306:752-755.
4. Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM,
Nagorney DM: Hepatic resection for colorectal metastases:
value for risk scoring systems?  Annals of Surgery 2007,
246:183-191.
5. Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM,
Vessella RL, Corey E: Metastases of prostate cancer express
estrogen receptor-beta.  Urology 2004, 64:814-820.
6. Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu G, Lu LJ, Shen ZZ, Ding J,
Shao ZM: ERbeta exerts multiple stimulative effects on
human breast carcinoma cells.  Oncogene 2004, 23:5799-5806.
7. Guerini V, Sau D, Scaccianoce E, Rusmini P, Ciana P, Maggi A, Martini
PG, Katzenellenbogen BS, Martini L, Motta M, Poletti A: The andro-
gen derivative 5alpha-androstane-3beta,17beta-diol inhibits
prostate cancer cell migration through activation of the
estrogen receptor beta subtype.  Cancer Research 2005,
65:5445-5453.
Down-regulation of MMP7 and ERβ levels in HT29 cells, following treatment with TAM, 5-FU or 12.5 μM 5-FU combined with indicated conce trations of TAMFigure 4
Down-regulation of MMP7 and ERβ levels in HT29 cells, following treatment with TAM, 5-FU or 12.5 μM 5-FU 
combined with indicated concentrations of TAM.Page 7 of 8
(page number not for citation purposes)
Journal of Experimental & Clinical Cancer Research 2009, 28:132 http://www.jeccr.com/content/28/1/132Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
8. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA:
Cloning of a novel receptor expressed in rat prostate and
ovary.  Proceedings of the National Academy of Sciences of the United
States of America 1996, 93:5925-5930.
9. Witte D, Chirala M, Younes A, Li Y, Younes M: Estrogen receptor
beta is expressed in human colorectal adenocarcinoma.
Human Pathology 2001, 32:940-944.
10. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML: Functional
estrogen receptor beta in colon cancer cells.  Biochemical & Bio-
physical Research Communications 1999, 261:521-527.
11. Qiu Y, Waters CE, Lewis AE, Langman MJ, Eggo MC: Oestrogen-
induced apoptosis in colonocytes expressing oestrogen
receptor beta.  Journal of Endocrinology 2002, 174:369-377.
12. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW: Selective loss
of estrogen receptor beta in malignant human colon.  Cancer
Research 2000, 60:245-248.
13. Imamov O, Morani A, Shim GJ, Omoto Y, Thulin-Andersson C,
Warner M, Gustafsson JA: Estrogen receptor beta regulates
epithelial cellular differentiation in the mouse ventral pros-
tate.  Proceedings of the National Academy of Sciences of the United
States of America 2004, 101:9375-9380.
14. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G,
Enmark E, Pettersson K, Warner M, Gustafsson JA: Mechanisms of
estrogen action.  Physiological Reviews 2001, 81:1535-1565.
15. Forster C, Makela S, Warri A, Kietz S, Becker D, Hultenby K, Warner
M, Gustafsson JA: Involvement of estrogen receptor beta in
terminal differentiation of mammary gland epithelium.  Pro-
ceedings of the National Academy of Sciences of the United States of Amer-
ica 2002, 99:15578-15583.
16. Weihua Z, Makela S, Andersson LC, Salmi S, Saji S, Webster JI, Jensen
EV, Nilsson S, Warner M, Gustafsson JA: A role for estrogen
receptor beta in the regulation of growth of the ventral pros-
tate.  Proceedings of the National Academy of Sciences of the United
States of America 2001, 98:6330-6335.
17. Shim GJ, Wang L, Andersson S, Nagy N, Kis LL, Zhang Q, Makela S,
Warner M, Gustafsson JA: Disruption of the estrogen receptor
beta gene in mice causes myeloproliferative disease resem-
bling chronic myeloid leukemia with lymphoid blast crisis.
Proceedings of the National Academy of Sciences of the United States of
America 2003, 100:6694-6699.
18. Beato M, Herrlich P, Schutz G: Steroid hormone receptors:
many actors in search of a plot.  Cell 1995, 83:851-857.
19. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ,
Scanlan TS: Differential ligand activation of estrogen recep-
tors ERalpha and ERbeta at AP1 sites.  Science 1997,
277:1508-1510.
20. Motylewska E, Lawnicka H, Melen-Mucha G: Oestradiol and
tamoxifen inhibit murine Colon 38 cancer growth and
increase the cytotoxic effect of fluorouracil.  Endokrynologia Pol-
ska 2007, 58:426-434.
21. Zucker S, Vacirca J: Role of matrix metalloproteinases (MMPs)
in colorectal cancer.  Cancer & Metastasis Reviews 2004,
23:101-117.
22. Malhotra S, Newman E, Eisenberg D, Scholes J, Wieczorek R, Mignatti
P, Shamamian P: Increased membrane type 1 matrix metallo-
proteinase expression from adenoma to colon cancer: a pos-
sible mechanism of neoplastic progression.  Diseases of the
Colon & Rectum 2002, 45:537-543.
23. Shirafuji Y, Tanabe H, Satchell DP, Henschen-Edman A, Wilson CL,
Ouellette AJ: Structural determinants of procryptdin recogni-
tion and cleavage by matrix metalloproteinase-7.  Journal of
Biological Chemistry 2003, 278:7910-7919.
24. Saitoh Y, Yanai H, Higaki S, Nohara H, Yoshida T, Okita K: Relation-
ship between matrix metalloproteinase-7 and pit pattern in
early stage colorectal cancer.  Gastrointestinal Endoscopy 2004,
59:385-392.
25. Ougolkov AV, Yamashita K, Mai M, Minamoto T: Oncogenic beta-
catenin and MMP-7 (matrilysin) cosegregate in late-stage
clinical colon cancer.  Gastroenterology 2002, 122:60-71.
26. Miyazaki K, Hattori Y, Umenishi F, Yasumitsu H, Umeda M: Purifica-
tion and characterization of extracellular matrix-degrading
metalloproteinase, matrin (pump-1), secreted from human
rectal carcinoma cell line.  Cancer Research 1990, 50:7758-7764.
27. Adachi Y, Itoh F, Yamamoto H, Iku S, Matsuno K, Arimura Y, Imai K:
Retinoic acids reduce matrilysin (matrix metalloproteinase
7) and inhibit tumor cell invasion in human colon cancer.
Tumour Biology 2001, 22:247-253.
28. Yamamoto H, Iku S, Adachi Y, Imsumran A, Taniguchi H, Nosho K,
Min Y, Horiuchi S, Yoshida M, Itoh F, Imai K: Association of trypsin
expression with tumour progression and matrilysin expres-
sion in human colorectal cancer.  Journal of Pathology 2003,
199:176-184.
29. Zeng ZS, Shu WP, Cohen AM, Guillem JG: Matrix metalloprotei-
nase-7 expression in colorectal cancer liver metastases: evi-
dence for involvement of MMP-7 activation in human cancer
metastases.  Clinical Cancer Research 2002, 8:144-148.
30. Gorodeski GI: Estrogen decrease in tight junctional resistance
involves matrix-metalloproteinase-7-mediated remodeling
of occludin.  Endocrinology 2007, 148:218-231.
31. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L Jr: A pharmacolog-
ical review of selective oestrogen receptor modulators.
Human Reproduction Update 2000, 6:212-224.
32. Wang JY, Viar MJ, Li J, Shi HJ, McCormack SA, Johnson LR:
Polyamines are necessary for normal expression of the
transforming growth factor-beta gene during cell migration.
American Journal of Physiology 1997, 272:G713-720.
33. Patel AR, Li J, Bass BL, Wang JY: Expression of the transforming
growth factor-beta gene during growth inhibition following
polyamine depletion.  American Journal of Physiology 1998,
275:C590-598.
34. Hsu HH, Cheng SF, Wu CC, Chu CH, Weng YJ, Lin CS, Lee SD, Wu
HC, Huang CY, Kuo WW: Apoptotic effects of over-expressed
estrogen receptor-beta on LoVo colon cancer cell is medi-
ated by p53 signalings in a ligand-dependent manner.  Chinese
Journal of Physiology 2006, 49:110-116.
35. Heslin MJ, Yan J, Johnson MR, Weiss H, Diasio RB, Urist MM: Role of
matrix metalloproteinases in colorectal carcinogenesis.
Annals of Surgery 2001, 233:786-792.
36. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Rubinfeld
B, Polakis P, Matrisian LM: The metalloproteinase matrilysin is a
target of beta-catenin transactivation in intestinal tumors.
Oncogene 1999, 18:2883-2891.
37. Leeman MF, Curran S, Murray GI: New insights into the roles of
matrix metalloproteinases in colorectal cancer develop-
ment and progression.  Journal of Pathology 2003, 201:528-534.Page 8 of 8
(page number not for citation purposes)
